• Users Online: 82
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Browse Articles Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2015  |  Volume : 6  |  Issue : 1  |  Page : 10

Comment on: Prevention of renal damage by treating hyperuricemia

1 Department of Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran
2 Medical Plants Research Center, Chronic Kidney Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 Medical Plants Research Center, Shahrekord University of Medical Sciences, Sharhekord, Iran

Date of Submission08-Mar-2014
Date of Acceptance07-Aug-2014
Date of Web Publication20-Feb-2015

Correspondence Address:
Mahmoud Rafieian-Kopaei
Medical Plants Research Center, Shahrekord University of Medical Sciences, Sharhekord
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2008-7802.151815

Rights and Permissions

How to cite this article:
Nasri H, Ardalan MR, Rafieian-Kopaei M. Comment on: Prevention of renal damage by treating hyperuricemia. Int J Prev Med 2015;6:10

How to cite this URL:
Nasri H, Ardalan MR, Rafieian-Kopaei M. Comment on: Prevention of renal damage by treating hyperuricemia. Int J Prev Med [serial online] 2015 [cited 2023 Mar 31];6:10. Available from: https://www.ijpvmjournal.net/text.asp?2015/6/1/10/151815


A recently published article by Nickavar, entitled "prevention of renal damage by treating hyperuricemia in the esteemed "International Journal of Preventive Medicine" was read with great interest. She presented the child with proteinuria, hypertension, and glomerular sclerosis secondary to hypouricosuric hyperuricemia, who was treated by uric acid lowering management. They observed the decrement of proteinuria significantly by uric acid lowering agents. [1] At this paper, I would like to remember a few points. Recently, much attention had been paid toward the impact of hyperuricemia on kidney injury. [2],[3] In addition to various well-known risk factors such as hypertension and diabetes, several "non-traditional" risk factors may contribute to the higher risk of renal injury compared to the general population. [4],[5],[6],[7],[8] In a study on 60 patients with type II diabetes without a history of gout, we detected a significant positive association between body mass index and serum uric acid levels (r = 0.428, P = 0.001). After adjustment for weight, a significant positive association of serum uric acid with level of proteinuria was seen (r = 0.47, P < 0.001) too, [9] moreover, the association of serum uric acid with level of blood pressure was significantly positive. [10] Accordingly, Jalalzadeh et al., conducted a single-blind, randomized cross-over clinical investigation consisting 55 hemodialysis patients with serum uric acid level >6.5 (men) and >5.5 mg/dL (women). [11] They detected the a reduction of blood pressure by allopurinol treatment in hemodialysis patients. [11] Thus, likewise to the beneficial effect of Allopurinal in study of Nickavar, this study also revealed that allopurinol therapy may act as a new potential therapeutic approach to control of blood pressure in patients on hemodialysis. [12],[13],[14] Interestingly it was shown that treatment of hyperuricemia increases 1,25(OH) 2 D levels, proposing that hyperuricemia may have a suppressive effect on 1-α hydroxylase activity. [15] It is possible that high plasma uric acid levels reduce 1,25(OH) 2 D levels by suppressing 1-α hydroxylase and, while low 1,25(OH) 2 D levels can stimulate parathyroid hormone (PTH) that high uric acid levels should be associated with elevated PTH levels too. [2],[15],[16],[17],[18],[19],[20],[21] In accord with this hypothesis, Chen et al., in in vivo study on Sprague Dawley rats, found uric acid suppresses 1-α hydroxylase in vitro and in vivo. [15] In fact, a reduction in 1,25(OH) 2 D secondary to reduced 1-α hydroxylase enzyme activity contributes to the development of secondary hyperparathyroidism in patients with chronic kidney disease. [2],[15],[16],[17],[18],[19],[20],[21] Indeed, the direct association of hyperuricemia and Vitamin D metabolism has two consequences. First, it is well understand that hyperuricemia by itself is an independent risk factor for kidney damage in various nephropathies like IgA nephropathy or diabetic kidney disease. [2],[16],[17],[18],[19],[20],[21],[22],[23],[24] Many studies, support the hypothesis that elevated uric acid levels might have an injurious effect, resulting to inflammation, endothelial dysfunction, and vascular disease. [2],[9],[11],[15],[16],[17] Second, except the deleterious effect of hyperuricemia on hypertension and aggravation of some type of nephropathies, its harmful effect of Vitamin D production is of significant importance. [15],[16],[17],[18],[19],[20],[21],[22],[23] Many studies had shown, support Vitamin D as a negative regulator of the circulating and local tissue renin-angiotensin system (RAS), since RAS has a critical implication in the physiology of sodium and volume homeostasis, hence, excess activity of RAS is associated with high blood pressure, kidney disease, and diabetes. [15],[16],[17],[18],[19],[20],[21],[22],[23],[24],[25],[26],[27],[28],[29],[30],[31] Thus, the cast presented by Nickavar, further supports the implication of hyperuricemia in the aggravation of kidney damage.

  References Top

Nickavar A. Prevention of renal damage by treating hyperuricemia. Int J Prev Med 2013;4:1318-20.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
Nasri H, Rafieian-Kopaei M. Hyperuricemia; a new look at an old problem. J Nephropharmacol 2012;1:13-4.  Back to cited text no. 2
Amiri M, Nasri H. Secondary hyperparathyroidism in chronic kidney disease patients; current knowledge. J Parathyr Dis 2014;2:1-2.  Back to cited text no. 3
Kari J. Epidemiology of chronic kidney disease in children. J Nephropathol 2012;1:162-3.  Back to cited text no. 4
Rastegari E, Nasri H. Association of serum leptin with serum C-reactive protein in hemodialysis patients. J Nephropharmacol 2012;1:19-21.  Back to cited text no. 5
Assadi F. The epidemic of pediatric chronic kidney disease: The danger of skepticism. J Nephropathol 2012;1:61-4.  Back to cited text no. 6
Hajivandi A, Amiri M. World Kidney Day 2014: Kidney disease and elderly. J Parathyr Dis 2014;2:3-4.  Back to cited text no. 7
Namjoo AR, MirVakili M, Shirzad H, Faghani M. Biochemical, liver and renal toxicities of Melissa officinals hydroalcoholic extract on balb/C mice. J Herb Med Pharmacol 2013;2:35-40.  Back to cited text no. 8
Behradmanesh S, Horestani MK, Baradaran A, Nasri H. Association of serum uric acid with proteinuria in type 2 diabetic patients. J Res Med Sci 2013;18:44-6.  Back to cited text no. 9
[PUBMED]  Medknow Journal  
Rafieian-Kopaei M, Behradmanesh S, Kheiri S, Nasri H. Association of serum uric acid with level of blood pressure in type 2 diabetic patients. Iran J Kidney Dis 2014;8:152-4.  Back to cited text no. 10
Jalalzadeh M, Nurcheshmeh Z, Mohammadi R, Mousavinasab N, Ghadiani MH. The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia. J Res Med Sci 2012;17:1039-46.  Back to cited text no. 11
[PUBMED]  Medknow Journal  
Nasri H, Ardalan MR. Significance of hyperuricemia in immunoglobulin a nephropathy. J Renal Inj Prev 2013;2:105-6.  Back to cited text no. 12
Baradaran A. Primary hyperparathyroidism and kidney; recent findings. J Parathyr Dis 2014;2:5-6.  Back to cited text no. 13
Nasri H. Correlation of serum magnesium with serum levels of 25-hydroxyvitamin D in hemodialysis patients. J Parathyr Dis 2014;2:11-3.  Back to cited text no. 14
Chen W, Roncal-Jimenez C, Lanaspa M, Gerard S, Chonchol M, Johnson RJ, et al. Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. Metabolism 2014;63:150-60.  Back to cited text no. 15
Baradaran A. Primary hyperparathyroidism and kidney; recent findings. J Parathyr Dis 2014;2:5-6.  Back to cited text no. 16
Tang Z, Cheng LT, Li HY, Wang T. Serum uric acid and endothelial dysfunction in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 2009;29:368-73.  Back to cited text no. 17
Nasri H. Commentary on: Is uric acid an indicator of metabolic syndrome in the first-degree relatives of patients with type 2 diabetes? J Res Med Sci 2013;18:267-8.  Back to cited text no. 18
[PUBMED]  Medknow Journal  
Kuo CF, Luo SF, See LC, Ko YS, Chen YM, Hwang JS, et al. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol 2011;40:116-21.  Back to cited text no. 19
Nasri H. Elevated serum parathyroid hormone is a heart risk factor in hemodialysis patients. J Parathyr Dis 2013;1:13-4.  Back to cited text no. 20
Pickering JW, Endre ZH. The definition and detection of acute kidney injury. J Renal Inj Prev 2014;3:21-5.  Back to cited text no. 21
Juraschek SP, Tunstall-Pedoe H, Woodward M. Serum uric acid and the risk of mortality during 23 years follow-up in the Scottish Heart Health Extended Cohort Study. Atherosclerosis 2014;233:623-9.  Back to cited text no. 22
Spasovski D. Renal markers for assessment of renal tubular and glomerular dysfunction. J Nephropharmacol 2013;2:23-5.  Back to cited text no. 23
Nasri H. The awareness of chronic kidney disease and aging; the focus of world kidney day in 2014. J Nephropharmacol 2014;3:1-2.  Back to cited text no. 24
Nasri H. Impact of diabetes mellitus on parathyroid hormone in hemodialysis patients. J Parathyr Dis 2013;2:9-11.  Back to cited text no. 25
Rafieian-Kopaei M, Nasri H. Vitamin D therapy in diabetic kidney disease. J Nephropharmacol 2014;3:3-4.  Back to cited text no. 26
Behradmanesh S, Nasri H. Association of serum calcium with level of blood pressure in type 2 diabetic patients. J Nephropathol 2013;2:254-7.  Back to cited text no. 27
Ouppatham S, Bancha S, Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population. J Postgrad Med 2008;54:259-62.  Back to cited text no. 28
[PUBMED]  Medknow Journal  
Nasri H, Rafieian-Kopaei M. Association of serum vitamin D level with age in individuals with normal renal function. J Nephropharmacol 2012;1:7-9.  Back to cited text no. 29
Nasri H, Rafieian-Kopaei M. Significant difference of serum 25-hydroxyvitamin D level in male hemodialysis patients with our without diabetes; a single center study. J Nephropharmacol 2012;1:3-4.  Back to cited text no. 30
Baradaran A. Beyond mineral metabolism, the bright immunomodulatory effect of vitamin D in renal disease. J Nephropharmacol 2012;1:17-8.  Back to cited text no. 31


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded212    
    Comments [Add]    

Recommend this journal